Vistin Pharma (VISTN) investor relations material

Market overview and diabetes trends

• Global diabetes prevalence is projected to rise from 589 million adults in 2024 to 853 million by 2050, with significant increases across all regions.

• Over 3.4 million diabetes-related deaths occurred in 2024, accounting for 9.3% of global deaths.

• Annual global diabetes spending exceeded USD 1 trillion in 2024, representing 12% of total health expenditure.

• Approximately 252 million adults are unaware they have diabetes, highlighting underdiagnosis.

• Global metformin API demand is expected to grow steadily at a 4-6% CAGR, reaching 104,000 metric tons by 2030.

Company positioning and operations

• Holds 8-10% global market share in metformin API, supplying over 20 million patients daily.

• Production capacity exceeds 6,000 metric tons, with recent investments doubling capacity.

• Manufacturing site in Norway uses 100% renewable hydropower, supporting ESG credentials.

• All products are exported globally, with a strong presence in Europe and Asia-Pacific.

• Factory is approved by major international regulatory authorities (FDA, EMEA, PMDA).

Financial performance and shareholder returns

• Revenues have grown from MNOK 305 in 2021 to a projected MNOK 452 in 2025.

• EBITDA growth has been volatile, impacted by plant upgrades and temporary closures.

• Earnings per share increased by ~200% from 2021 to 2025, with rising annual dividends.

• Maintains a strong balance sheet with a 75% equity ratio, no interest-bearing debt, and net cash.

• Dividend payments have increased annually, with a proposed NOK 1.50 per share for 2026.